-DNA India is expected to bear the brunt of $160 billion trade-distorting farm subsidies provided by developed nations like the US At a time when angry farmer protests seeking an increase in the Minimum Support Price (MSP) for all crops is on an upswing, India faces an uphill task to protect its food procurement operations at the forthcoming Buenos Aires Ministerial of the World Trade Organisation (WTO) from December 10-13. At...

-The Indian Express Governments have not acted on recommendations of committees on farmer welfare How many more farmers must die before the prime minister condescends to take notice? How many rats must the protesting Tamil Nadu farmers at Jantar Mantar eat before the government acts? How many more fake farm loan waiver schemes will be announced before the cabinet realises that farmers cannot be fooled anymore? Despite 300,000 farmers taking their lives...

-TheWire.in Developed countries want to include new issues like e-commerce, investment facilitation and government procurement in the discussion. New Delhi: Battle lines have been drawn between developed and developing countries over the agenda for the forthcoming WTO ministerial conference at Buenos Aires, with India saying it will oppose discussion on new issues like e-commerce, investment facilitation and government procurement. If India remains firm on its stand, the upcoming ministerial, to be held from...

-The Hindu Aadhaar-based Biometric Authentication does nothing in the battle against graft — there are better alternatives In a sickening way, October 2017 was like October 2002. Fifteen years ago, in Rajasthan’s Baran and Udaipur districts, there was a spate of starvation deaths. The government of the time made up fanciful stories to deny that the deaths had anything to do with hunger or government failure. In October 2017, the death of an 11-year-old...

-The Hindu Business Line Public procurement at a negotiated price is a better option. Price curbs deter producers and don’t check pharmacy margins The Government’s attempt to keep the prices of essential medicines affordable and curb the extraordinary returns earned by private healthcare providers through price controls has started an inexorable process whose end does not seem in sight. Will these moves eventually be counter-productive? First came the move to extend the scope...